双时相门冬胰岛素50注射液治疗2型糖尿病的临床研究
发布时间：2018-10-25 18:23
【摘要】：目的比较双时相门冬胰岛素50注射液与双时相人胰岛素50注射剂治疗2型糖尿病的临床疗效及安全性。方法将112例口服二甲双胍血糖控制不达标的2型糖尿病患者随机分为对照组56例和试验组56例。对照组予以0.4U·kg~(-1)双时相人胰岛素50,bid(早、晚餐前5 min),皮下注射;试验组予以双时相门冬胰岛素50,早餐前30 min予以0.4 U·kg~(-1),晚餐前30 min予以0.2U·kg~(-1),皮下注射。2组患者均治疗36周。比较2组患者的餐后2 h血糖(2 h PG)、可溶性细胞间黏附分子1(s ICAM~(-1))、可溶性血管细胞间黏附分子1(s VCAM~(-1))、单核细胞趋化蛋白~(-1)(MCP~(-1))和肿瘤坏死因子(TNF-α)的水平,以及药物不良反应的发生情况。结果治疗后,试验组和对照组的2 h PG分别为(8.31±2.43),(11.08±2.43)mmol·L~(-1),差异有统计学意义(P0.05)。治疗后,试验组和对照组的s ICAM~(-1)分别为(229.82±7.61)和(249.45±8.05)μg·L~(-1),s VCAM~(-1)分别为(531.58±11.45)和(559.82±15.42)μg·L~(-1),MCP~(-1)分别为(371.46±9.76)和(399.64±12.85)μg·L~(-1);TNF-α分别为(12.05±1.18)和(15.81±1.76)μg·L~(-1),差异均有统计学意义(均P0.05)。2组患者的药物不良反应均以低血糖为主,试验组和对照组的药物不良反应发生率分别为5.36%和14.29%,差异无统计学意义(P0.05)。结论与双时相人胰岛素50注射剂相比,双时相门冬胰岛素50注射液可显著降低患者的2 h PG和血清s ICAM~(-1)、s VCAM~(-1)、MCP~(-1)、TNF-α的水平,且不增加药物不良反应的发生率。
[Abstract]:Objective to compare the clinical efficacy and safety of dual phase aspartate insulin 50 injection and dual phase human insulin 50 injection in the treatment of type 2 diabetes. Methods 112 patients with type 2 diabetes mellitus were randomly divided into control group (n = 56) and experimental group (n = 56). In the control group, 0.4 U kg~ (-1) human insulin was injected subcutaneously 5 min), before dinner. The experimental group was treated with double-phase aspartic insulin 50, 0.4 U kg~ (-1) 30 min before breakfast and 0.2 U kg~ (-1) 30 min before dinner. The patients in both groups were treated for 36 weeks. Two hours postprandial blood glucose (2 h PG), soluble intercellular adhesion molecule-1 (s ICAM~ (-1),) soluble vascular intercellular adhesion molecule-1 (sVCAM~ (-1),) was compared between the two groups. The levels of monocyte chemoattractant protein-1 (MCP~ (-1) and tumor necrosis factor (TNF- 伪), and the occurrence of adverse drug reactions. Results after treatment, the PG of the experimental group and the control group were (8.31 卤2.43), (11.08 卤2.43) mmol L ~ (-1), respectively. The difference was statistically significant (P0.05). After treatment, s ICAM~ (-1) was (229.82 卤7.61) 渭 g L ~ (-1) and (249.45 卤8.05) 渭 g L ~ (-1), s VCAM~ (-1) in the experimental group and the control group respectively (531.58 卤11.45) and (559.82 卤15.42) 渭 g L ~ (-1), respectively. MCP~ (-1) was (371.46 卤9.76) 渭 g / L ~ (-1) and (399.64 卤12.85) 渭 g / L ~ (-1), respectively. TNF- 伪 was (12.05 卤1.18) 渭 g / L ~ (-1) and (15.81 卤1.76) 渭 g / L ~ (-1), respectively (P0.05). The incidence of adverse drug reactions in the test group and the control group were 5.36% and 14.29%, respectively. The difference was not statistically significant (P0.05). Conclusion compared with the dual phase human insulin 50 injection, the serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1), TNF- 伪) levels were significantly lower in the patients than in the two phase aspartate insulin 50 injection at 2 h after injection, and the levels of serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1) and TNF- 伪) were significantly decreased. The incidence of adverse drug reactions was not increased.
【作者单位】： 重庆市急救医疗中心检验科;四川省人民医院儿科;
【基金】：国家自然科学基金资助项目(81300238)
【分类号】：R587.1
[Abstract]:Objective to compare the clinical efficacy and safety of dual phase aspartate insulin 50 injection and dual phase human insulin 50 injection in the treatment of type 2 diabetes. Methods 112 patients with type 2 diabetes mellitus were randomly divided into control group (n = 56) and experimental group (n = 56). In the control group, 0.4 U kg~ (-1) human insulin was injected subcutaneously 5 min), before dinner. The experimental group was treated with double-phase aspartic insulin 50, 0.4 U kg~ (-1) 30 min before breakfast and 0.2 U kg~ (-1) 30 min before dinner. The patients in both groups were treated for 36 weeks. Two hours postprandial blood glucose (2 h PG), soluble intercellular adhesion molecule-1 (s ICAM~ (-1),) soluble vascular intercellular adhesion molecule-1 (sVCAM~ (-1),) was compared between the two groups. The levels of monocyte chemoattractant protein-1 (MCP~ (-1) and tumor necrosis factor (TNF- 伪), and the occurrence of adverse drug reactions. Results after treatment, the PG of the experimental group and the control group were (8.31 卤2.43), (11.08 卤2.43) mmol L ~ (-1), respectively. The difference was statistically significant (P0.05). After treatment, s ICAM~ (-1) was (229.82 卤7.61) 渭 g L ~ (-1) and (249.45 卤8.05) 渭 g L ~ (-1), s VCAM~ (-1) in the experimental group and the control group respectively (531.58 卤11.45) and (559.82 卤15.42) 渭 g L ~ (-1), respectively. MCP~ (-1) was (371.46 卤9.76) 渭 g / L ~ (-1) and (399.64 卤12.85) 渭 g / L ~ (-1), respectively. TNF- 伪 was (12.05 卤1.18) 渭 g / L ~ (-1) and (15.81 卤1.76) 渭 g / L ~ (-1), respectively (P0.05). The incidence of adverse drug reactions in the test group and the control group were 5.36% and 14.29%, respectively. The difference was not statistically significant (P0.05). Conclusion compared with the dual phase human insulin 50 injection, the serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1), TNF- 伪) levels were significantly lower in the patients than in the two phase aspartate insulin 50 injection at 2 h after injection, and the levels of serum s ICAM~ (-1), s VCAM~ (-1), MCP~ (-1) and TNF- 伪) were significantly decreased. The incidence of adverse drug reactions was not increased.
【作者单位】： 重庆市急救医疗中心检验科;四川省人民医院儿科;
【基金】：国家自然科学基金资助项目(81300238)
【分类号】：R587.1
【参考文献】
相关期刊论文 前1条
1 王立坤;武雪亮;杨占清;张军;史丽;杨瑞敏;王义成;;2型糖尿病患者血清抵抗素和瘦素及脂联素水平与颈动脉斑块的相关性研究[J];中国临床药理学杂志;2017年04期
【共引文献】
相关期刊论文 前1条
1 杨丽;唐静;候f ;;双时相门冬胰岛素50注射液治疗2型糖尿病的临床研究[J];中国临床药理学杂志;2017年15期
【二级参考文献】
相关期刊论文 前2条
1 宋爱霞;纪蓉;刘俊峰;薛茜;;脑梗死患者血清生物标志物水平与颈动脉斑块的相关性研究[J];中国临床药理学杂志;2016年03期
2 周小爱;朱绥;朱长远;王筱t，
本文编号：2294467
本文链接：https://www.wllwen.com/yixuelunwen/nfm/2294467.html
最近更新
教材专著
